Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.08
MKGAY's Cash to Debt is ranked lower than
94% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. MKGAY: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
MKGAY' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 9999.00 Max: No Debt
Current: 0.08
Equity to Asset 0.34
MKGAY's Equity to Asset is ranked lower than
85% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MKGAY: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
MKGAY' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.48 Max: 0.57
Current: 0.34
0.34
0.57
Interest Coverage 9.75
MKGAY's Interest Coverage is ranked lower than
65% of the 475 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.69 vs. MKGAY: 9.75 )
Ranked among companies with meaningful Interest Coverage only.
MKGAY' s Interest Coverage Range Over the Past 10 Years
Min: 3.13  Med: 4.71 Max: 21.55
Current: 9.75
3.13
21.55
F-Score: 5
Z-Score: 0.78
M-Score: -2.24
WACC vs ROIC
6.97%
9.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 16.43
MKGAY's Operating margin (%) is ranked higher than
74% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. MKGAY: 16.43 )
Ranked among companies with meaningful Operating margin (%) only.
MKGAY' s Operating margin (%) Range Over the Past 10 Years
Min: 8.01  Med: 12.89 Max: 17.67
Current: 16.43
8.01
17.67
Net-margin (%) 10.57
MKGAY's Net-margin (%) is ranked higher than
67% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. MKGAY: 10.57 )
Ranked among companies with meaningful Net-margin (%) only.
MKGAY' s Net-margin (%) Range Over the Past 10 Years
Min: 4.86  Med: 7.79 Max: 49.88
Current: 10.57
4.86
49.88
ROE (%) 10.65
MKGAY's ROE (%) is ranked higher than
63% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. MKGAY: 10.65 )
Ranked among companies with meaningful ROE (%) only.
MKGAY' s ROE (%) Range Over the Past 10 Years
Min: 3.86  Med: 7.74 Max: 56.55
Current: 10.65
3.86
56.55
ROA (%) 4.24
MKGAY's ROA (%) is ranked higher than
53% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. MKGAY: 4.24 )
Ranked among companies with meaningful ROA (%) only.
MKGAY' s ROA (%) Range Over the Past 10 Years
Min: 2.33  Med: 3.38 Max: 30.58
Current: 4.24
2.33
30.58
ROC (Joel Greenblatt) (%) 47.11
MKGAY's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. MKGAY: 47.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MKGAY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 18.19  Med: 34.09 Max: 54.2
Current: 47.11
18.19
54.2
Revenue Growth (3Y)(%) 4.80
MKGAY's Revenue Growth (3Y)(%) is ranked lower than
53% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. MKGAY: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MKGAY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.6  Med: 4.80 Max: 13
Current: 4.8
-10.6
13
EBITDA Growth (3Y)(%) 11.70
MKGAY's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. MKGAY: 11.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MKGAY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 1  Med: 9.00 Max: 13.3
Current: 11.7
1
13.3
EPS Growth (3Y)(%) 25.00
MKGAY's EPS Growth (3Y)(%) is ranked higher than
76% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. MKGAY: 25.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MKGAY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.8  Med: 23.30 Max: 66.4
Current: 25
-30.8
66.4
» MKGAY's 10-Y Financials

Financials (Next Earnings Date: 2016-10-12)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MKGAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:PRGO, OTCPK:APNHY, OTCPK:SGIOF, OTCPK:ESALY, OTCPK:MTZPY, NYSE:RDY, OTCPK:TAISF, OTCPK:HLUYY, OTCPK:HKMPY, NYSE:VRX, NYSE:MNK, OTCPK:MDABY, NYSE:TARO, OTCPK:SFOSF, NAS:OPK, OTCPK:HYPMY, OTCPK:DNPUF, OTCPK:IPSEY, OTCPK:HTSUF, NAS:NBIX » details
Traded in other countries:MRK.Germany, MER.Switzerland, 0O14.UK,
Merck KGaA is a pharmaceutical and chemical company. It produces prescription drugs, over-the-counter products and specialty products for the electronics, printing, coatings, cosmetics, food, pharmaceutical and biotechnology industries.

Merck KGaA was founded in 1668 in Darmstadt. It is a pharmaceutical and chemical company. The Company operates as a manufacturer of standard and specialty chemicals for the laboratory and industry. The Company researches drugs in the areas oncology and neurodegenerative as well as autoimmune and inflammatory diseases. Its operating business segments are Healthcare, Life Science and Performance Materials. The Healthcare business sector comprises the businesses with prescription and over-the-counter pharmaceuticals and biopharmaceuticals as well as allergy products. The Life Science business sector offers solutions to research and analytical laboratories in the pharmaceutical /biotechnology industry or in academic institutions, and customers manufacturing large- and small-molecule drugs. The Performance Materials business sector consists of the entire specialty chemicals business. The Company also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for flat screens and the pharmaceutical, food, cosmetics, packaging, and coatings.

Ratios

vs
industry
vs
history
P/E(ttm) 30.57
MKGAY's P/E(ttm) is ranked lower than
53% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.41 vs. MKGAY: 30.57 )
Ranked among companies with meaningful P/E(ttm) only.
MKGAY' s P/E(ttm) Range Over the Past 10 Years
Min: 10.19  Med: 27.23 Max: 52.48
Current: 30.57
10.19
52.48
Forward P/E 17.24
MKGAY's Forward P/E is ranked lower than
53% of the 81 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. MKGAY: 17.24 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.66
MKGAY's PE(NRI) is ranked lower than
52% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.39 vs. MKGAY: 30.66 )
Ranked among companies with meaningful PE(NRI) only.
MKGAY' s PE(NRI) Range Over the Past 10 Years
Min: 10.19  Med: 27.23 Max: 51.95
Current: 30.66
10.19
51.95
Price/Owner Earnings (ttm) 6.00
MKGAY's Price/Owner Earnings (ttm) is ranked higher than
94% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.57 vs. MKGAY: 6.00 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MKGAY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.02  Med: 12.28 Max: 23.46
Current: 6
3.02
23.46
P/B 1.05
MKGAY's P/B is ranked higher than
86% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. MKGAY: 1.05 )
Ranked among companies with meaningful P/B only.
MKGAY' s P/B Range Over the Past 10 Years
Min: 0.35  Med: 0.68 Max: 1.05
Current: 1.05
0.35
1.05
P/S 1.94
MKGAY's P/S is ranked higher than
64% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. MKGAY: 1.94 )
Ranked among companies with meaningful P/S only.
MKGAY' s P/S Range Over the Past 10 Years
Min: 0.59  Med: 1.77 Max: 7.95
Current: 1.94
0.59
7.95
PFCF 22.88
MKGAY's PFCF is ranked higher than
51% of the 221 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.52 vs. MKGAY: 22.88 )
Ranked among companies with meaningful PFCF only.
MKGAY' s PFCF Range Over the Past 10 Years
Min: 7.13  Med: 15.19 Max: 88.72
Current: 22.88
7.13
88.72
POCF 14.05
MKGAY's POCF is ranked higher than
60% of the 292 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.35 vs. MKGAY: 14.05 )
Ranked among companies with meaningful POCF only.
MKGAY' s POCF Range Over the Past 10 Years
Min: 5.87  Med: 10.31 Max: 52.28
Current: 14.05
5.87
52.28
EV-to-EBIT 9.87
MKGAY's EV-to-EBIT is ranked higher than
82% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.71 vs. MKGAY: 9.87 )
Ranked among companies with meaningful EV-to-EBIT only.
MKGAY' s EV-to-EBIT Range Over the Past 10 Years
Min: 3.1  Med: 15.05 Max: 114.3
Current: 9.87
3.1
114.3
EV-to-EBITDA 5.61
MKGAY's EV-to-EBITDA is ranked higher than
93% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. MKGAY: 5.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
MKGAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2  Med: 6.50 Max: 41.9
Current: 5.61
2
41.9
PEG 4.08
MKGAY's PEG is ranked lower than
72% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.01 vs. MKGAY: 4.08 )
Ranked among companies with meaningful PEG only.
MKGAY' s PEG Range Over the Past 10 Years
Min: 0.21  Med: 1.69 Max: 4.14
Current: 4.08
0.21
4.14
Current Ratio 0.82
MKGAY's Current Ratio is ranked lower than
93% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. MKGAY: 0.82 )
Ranked among companies with meaningful Current Ratio only.
MKGAY' s Current Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.66 Max: 3.15
Current: 0.82
0.78
3.15
Quick Ratio 0.53
MKGAY's Quick Ratio is ranked lower than
95% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. MKGAY: 0.53 )
Ranked among companies with meaningful Quick Ratio only.
MKGAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.23 Max: 2.81
Current: 0.53
0.5
2.81
Days Inventory 175.90
MKGAY's Days Inventory is ranked lower than
76% of the 666 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. MKGAY: 175.90 )
Ranked among companies with meaningful Days Inventory only.
MKGAY' s Days Inventory Range Over the Past 10 Years
Min: 162.19  Med: 205.91 Max: 249.59
Current: 175.9
162.19
249.59
Days Sales Outstanding 77.48
MKGAY's Days Sales Outstanding is ranked lower than
53% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.90 vs. MKGAY: 77.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
MKGAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.5  Med: 75.44 Max: 90.21
Current: 77.48
66.5
90.21
Days Payable 144.92
MKGAY's Days Payable is ranked higher than
84% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.26 vs. MKGAY: 144.92 )
Ranked among companies with meaningful Days Payable only.
MKGAY' s Days Payable Range Over the Past 10 Years
Min: 91.94  Med: 160.46 Max: 183.63
Current: 144.92
91.94
183.63

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.10
MKGAY's Dividend Yield is ranked lower than
61% of the 603 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MKGAY: 1.10 )
Ranked among companies with meaningful Dividend Yield only.
MKGAY' s Dividend Yield Range Over the Past 10 Years
Min: 0.85  Med: 1.42 Max: 5.19
Current: 1.1
0.85
5.19
Dividend Payout 0.30
MKGAY's Dividend Payout is ranked higher than
56% of the 379 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.34 vs. MKGAY: 0.30 )
Ranked among companies with meaningful Dividend Payout only.
MKGAY' s Dividend Payout Range Over the Past 10 Years
Min: 0.88  Med: 1.31 Max: 5.77
Current: 0.3
0.88
5.77
Dividend Growth (3y) 10.10
MKGAY's Dividend Growth (3y) is ranked higher than
58% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. MKGAY: 10.10 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MKGAY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 32.2
Current: 10.1
0
32.2
Forward Dividend Yield 1.11
MKGAY's Forward Dividend Yield is ranked lower than
64% of the 578 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.54 vs. MKGAY: 1.11 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.74
MKGAY's Yield on cost (5-Year) is ranked higher than
64% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. MKGAY: 2.74 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MKGAY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.12  Med: 3.53 Max: 12.91
Current: 2.74
2.12
12.91

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.38
MKGAY's Price/Projected FCF is ranked higher than
96% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. MKGAY: 0.38 )
Ranked among companies with meaningful Price/Projected FCF only.
MKGAY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.29  Med: 1.30 Max: 1.52
Current: 0.38
0.29
1.52
Price/DCF (Earnings Based) 2.82
MKGAY's Price/DCF (Earnings Based) is ranked lower than
88% of the 80 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.31 vs. MKGAY: 2.82 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.10
MKGAY's Price/Median PS Value is ranked higher than
53% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. MKGAY: 1.10 )
Ranked among companies with meaningful Price/Median PS Value only.
MKGAY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 0.99 Max: 4.43
Current: 1.1
0.36
4.43
Price/Peter Lynch Fair Value 2.08
MKGAY's Price/Peter Lynch Fair Value is ranked lower than
63% of the 173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. MKGAY: 2.08 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MKGAY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.44  Med: 1.63 Max: 4.07
Current: 2.08
0.44
4.07
Earnings Yield (Greenblatt) (%) 10.17
MKGAY's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MKGAY: 10.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MKGAY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.9  Med: 6.65 Max: 32.3
Current: 10.17
0.9
32.3
Forward Rate of Return (Yacktman) (%) 19.19
MKGAY's Forward Rate of Return (Yacktman) (%) is ranked higher than
74% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. MKGAY: 19.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MKGAY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.2  Med: 20.80 Max: 54.7
Current: 19.19
12.2
54.7

More Statistics

Revenue (TTM) (Mil) $14,970
EPS (TTM) $ 1.22
Beta1.13
Short Percentage of Float0.00%
52-Week Range $26.91 - 36.15
Shares Outstanding (Mil)387.77

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 16,613 17,131 17,569
EPS ($) 2.12 2.27 2.47
EPS w/o NRI ($) 2.12 2.27 2.47
EPS Growth Rate
(3Y to 5Y Estimate)
10.04%
Dividends Per Share ($) 0.47 0.49 0.58
» More Articles for OTCPK:MKGAY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China Jul 28 2016
Merck Biopharma Innovation Cup Honors Young Scientists Jul 26 2016
Merck Receives European Medicines Agency Acceptance for Review of Marketing Authorization... Jul 18 2016
Dietmar Eidens Appointed Chief HR Officer (CHRO) of Merck Jul 15 2016
Merck Advances Water Purification Systems with New High-Throughput Line Jul 13 2016
Merck Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables Jul 12 2016
Merck and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian... Jul 06 2016
Merck Commits €1.5 million to the Grant for Fertility Innovation (GFI) for 2016/17 Jul 06 2016
Juniper Pharmaceuticals Announces that Merck KGaA, Darmstadt, Germany, has Obtained Regulatory... Jul 05 2016
Merck and University of Nairobi to Start Medical Oncology Fellowship Program Jul 01 2016
Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves... Jul 01 2016
Successful Cooperation Between Merck and Agrimer in Marine-Derived Dermocosmetic Active Ingredients Jul 01 2016
Merck KGaA, Darmstadt, Germany, Welcomes ZEISS and Hamilton Thorne as New Members of the Global... Jun 30 2016
Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance Jun 30 2016
Merck Receives Frost & Sullivan Award for Meoxal® and Xirallic® NXT Lines Jun 29 2016
Merck Expands Industry-Leading Emprove® Program to Include Filtration and Single-Use Products Jun 28 2016
Merck to Develop Next-Generation Purification Processes with International Vaccine Institute Jun 28 2016
ETF’s with exposure to Merck KGaA : June 20, 2016 Jun 20 2016
Merck Family Foundation Established Jun 17 2016
Merck in Agreement with HAPPYneuron to Offer First-of-its Kind e-Health Solution for People Living... Jun 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)